ArticleFrontiers in tuberculosis2024
Analyses of blood-derived host biomarkers for pulmonary tuberculosis diagnosis in human immunodeficiency virus co-infected individuals in sub-Saharan Africa: a systematic review and meta-analysis.
Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: Our objective was to conduct a review of host blood-derived biomarkers as potential diagnostic targets for pulmonary TB and as alternative tests to identify active tuberculosis in HIV co-infected individuals. Methods: A systematic review and meta-analysis of host blood-derived biomarkers with potential for diagnosis of active tuberculosis in HIV co-infected individuals was conducted. Cochrane Library, Embase, MEDLINE, PubMed and Web of Science databases were searched up to 7 November 2023. A hierarchical summary receiver operating characteristic (HSROC) model was used to evaluate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) of the following potential biomarkers: C-reactive protein (CRP), Interferon gamma induced protein-10 (IP-10), Neopterin, IGRA, Kynurenine to tryptophan (K/T) ratio and use of different panels of combined biomarkers; including 5 biomarker panel (IL-6, INF-y, MIG, CRP, and IL-18), 4 biomarker panel (IL-6, IL-21, INF-y, IL-1a), 6 biomarker panel (APO-ACIII, CXCL1, CXCL9, CCL8, CCL-1, and CD56), and 9 biomarker panel (Alpha-2-macroglobulin, fibrinogen, CRP, MMP-a, transthyretin, complement factor H, INF-y, IP-10, and TNF-α). Results: Twenty-three studies were included. The pooled sensitivity of CRP, IP-10, Neopterin, combined biomarker signatures, IGRA and K/T ratio were 77% (60-88), 79% (72 - 84), 82% (43-96), 78% (64-88), 71% (65-76), 95% (90-98), respectively and the pooled specificity were 90% (80-96), 82% (59-93), 42% (22-66), 85% (73-92), 33% (18-54), and 95% (82-99), respectively. Conclusion: CRP, IP-10, K/T ratio and the panels of multiple combined biomarkers that include the following cytokines, chemokines, and acute phase proteins IL-6, INF-y, MIG, CRP, IL-18, IL-21, IL-1a, APO-ACIII, CXCL1, CXCL9, CCL8, CCL-1, CD56, Alpha-2-macroglobulin, fibrinogen, MMP-a, transthyretin, complement factor H, IP-10, and TNF-α are potential blood biomarkers that can aid TB diagnosis in HIV co-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.